Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The long-term goal of this work is to develop a potassium (K)-based intra-articular (IA) injection for osteoarthritis treatment. Within this context, the objectives of this study were to (1) demonstrate that hyperosmolar K solutions can suppress proinflammatory macrophage activation and (2) evaluate the therapeutic potential of a hyperosmolar K solution relative to a clinically utilized drug-based (methylprednisolone acetate [MPA]-a corticosteroid) or cell-based (human mesenchymal stem cell [hMSC]) IA injectable. A 3D in vitro model with poly(ethylene glycol) diacrylate hydrogels encapsulated with proinflammatory interferon-gamma (IFN)-stimulated macrophages (M(IFN)s) was utilized. Long-term changes in cell phenotype in response to short-term stimulation (i.e., mimicking an IA injection) were assessed following treatment with 80 mM K gluconate, hMSCs, or MPA. Addition of 80 mM K gluconate to culture media significantly reduced iNOS and TNF protein levels in M(IFN)s. Furthermore, short-term stimulation with K gluconate elicited a significant increase in the anti/proinflammatory cytokine profile in M(IFN)s, a response that is not noticed with either clinically utilized MPA or an hMSC injectable. Hyperosmolar K solutions are capable of attenuating proinflammatory macrophage activation. Moreover, when evaluated in an in vitro setting mimicking an IA injection, K performed significantly better than hMSCs or the corticosteroid MPA. Cumulatively, these results support further development and application of a K-based IA injection toward osteoarthritis research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150937PMC
http://dx.doi.org/10.1089/ten.TEA.2017.0390DOI Listing

Publication Analysis

Top Keywords

injection osteoarthritis
12
intra-articular injection
8
hyperosmolar solutions
8
proinflammatory macrophage
8
macrophage activation
8
clinically utilized
8
short-term stimulation
8
mimicking injection
8
injection
5
initial vitro
4

Similar Publications

Purpose: This European Society of Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) formal consensus aims to provide evidence- and expert opinion-based recommendations for the use of point-of-care- and expanded-cell-based therapy (CBT) in the treatment of knee osteoarthritis (OA), focusing on indications, preparation, and administration.

Methods: A multidisciplinary group of 77 leading experts in musculoskeletal regenerative medicine from 22 European Countries formed a steering group, a rating group, and a reader group. The steering group developed 23 questions, originating from 27 statements.

View Article and Find Full Text PDF

Heat shock protein family A member 4-like (HSPA4L) has been shown to be overexpressed in osteoarthritis (OA) patients, but its role in OA process still unknown. Chondrocytes were stimulated with interleukin-1β (IL-1β) to mimic OA cell model in vitro, and rat was injected with monosodium iodoacetate (MIA) to construct OA rat model in vivo. The expression of HSPA4L, methyltransferase-like 3 (METTL3) and extracellular matrix (ECM)-related markers was examined by qRT-PCR or western blot.

View Article and Find Full Text PDF

Musculoskeletal disorders, including bone fractures, osteoarthritis, and muscle injuries, represent a leading cause of global disability, revealing the urgency for advanced therapeutic solutions. However, current therapies face limitations including donor-site morbidity, immune rejection, and inadequate mimicry of dynamic tissue repair processes. DNA-based hydrogels emerge as transformative platforms for musculoskeletal reconstruction, with their sequence programmability, dynamic adaptability, and biocompatibility to balance structural support and biological functions.

View Article and Find Full Text PDF

Purpose: To assess the characteristics and effectiveness of low-cost platelet-rich plasma (LC-PRP) for knee osteoarthritis (OA) by evaluating its composition and effect on pain, function, satisfaction, safety and cost-effectiveness.

Methods: Level IV evidence single-arm prospective cohort pilot study of 20 subjects (30 knees total) with mild-to-moderate knee OA. Two LC-PRP injections were performed, 3 weeks apart.

View Article and Find Full Text PDF

Purpose: To assess the pharmacodynamic effects and therapeutic mechanisms of modified Fuzi decoction (MFZD) in osteoarthritis (OA), particularly OA-related inflammation.

Methods: The main components of MFZD were identified using Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS). An OA model was established in Sprague-Dawley rats via intra-articular injection of monoiodoacetate (MIA) to evaluate the anti-OA efficacy of MFZD via gavage.

View Article and Find Full Text PDF